Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 1580 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv1580
  2. Study sites revised (1169)v1579
  3. Start date: Jun 1, 2007 to Jul 19, 2007
    • Trial status: Active, Not Recruiting to Completed
    • Study completion date changed from estimate of Oct 16, 2025 to Jan 31, 2025
    • Study sites revised (1169)
    v1578
  4. Study sites revised (1169)v1577
  5. Study sites revised (1169)v1576
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (1169)v1575
  2. Study completion date: Oct 16, 2024 to Oct 16, 2025
    • Study sites revised (1169)
    v1574
  3. Study sites: 1175 to 1169v1573
  4. Study sites revised (1175)v1572
  5. Re-verified, no change to tracked fieldsv1571
  6. Study sites revised (1175)v1570
  7. Study sites revised (1175)v1569
  8. Study sites revised (1175)v1568
  9. Study sites revised (1175)v1567
  10. Study sites revised (1175)v1566
  11. Study sites revised (1175)v1565
  12. Study sites revised (1175)v1564
  13. Study sites revised (1175)v1563
  14. Study sites revised (1175)v1562
  15. Re-verified, no change to tracked fieldsv1561
  16. Study sites revised (1175)v1560
  17. Study sites revised (1175)v1559
  18. Study sites revised (1175)v1558
  19. Re-verified, no change to tracked fieldsv1557
  20. Study completion date: Oct 16, 2023 to Oct 16, 2024v1556
  21. Site details revised at 1 of 1175 sitesv1555
  22. Study sites revised (1175)v1554
  23. Study sites revised (1175)v1553
  24. Study sites revised (1175)v1552
  25. Study sites revised (1175)v1551
  26. Re-verified, no change to tracked fieldsv1550
  27. Study sites revised (1175)v1549
  28. Study sites revised (1175)v1548
  29. Study sites revised (1175)v1547
  30. Study sites revised (1175)v1546
  31. Study sites revised (1175)v1545
  32. Study sites revised (1175)v1544
  33. Study sites revised (1175)v1543
  34. Study sites revised (1175)v1542
  35. 2 versions Re-verified since Jul 23, 2022, no change to tracked fieldsv1540-v1541
  36. Study sites revised (1175)v1539
  37. Study sites revised (1175)v1538
  38. Re-verified, no change to tracked fieldsv1537
  39. Study sites revised (1175)v1536
  40. Study sites revised (1175)v1535
  41. Study sites revised (1175)v1534
  42. Re-verified, no change to tracked fieldsv1533
  43. Study sites revised (1175)v1532
  44. Study sites revised (1175)v1531
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
Trial Details
NCT Number NCT00324805
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Cancer and Leukemia Group B, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Conditions
(from sponsor)		 Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 1,501 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov